RamAtezo-1: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

• Sponsor: Washington University School of Medicine (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03689855
• Collaborator: Eli Lilly and Company (Industry)
• Enrollment: 21
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 58.7
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients previously treated with ICB.

Condition or Disease	Intervention/Treatment	Phase
Non-small Cell Lung Cancer; Non Small Cell Lung Cancer; NSCLC	Drug: Ramucirumab; Drug: Atezolizumab; Procedure: Peripheral blood draw; Procedure: Biopsy	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 21 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
• Actual Study Start Date: Jun 5, 2019
• Actual Primary Completion Date: Jul 16, 2021
• Anticipated Study Completion Date: Apr 25, 2024

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Ramucirumab + Atezolizumab Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.

Drug: Ramucirumab; Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.; Other Names: Cyramza ; Drug: Atezolizumab; The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).; Other Names: Tecentriq ; Procedure: Peripheral blood draw; -Baseline and Cycle 2 Day 1; Procedure: Biopsy; If archival biopsy tissue not available, participant will undergo biopsy at baseline When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan.

Outcome Measures

Primary Outcome Measures

1. Overall Response Rate (ORR) [At 6 weeks]

   ORR: percentage of participants with a complete or partial response Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures

1. Clinical Benefit Rate (CBR) [At 6 weeks]

   CBR is defined as the percentage of patients who have achieved responses (complete or partial) or stable disease. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

2. Toxicity and Tolerability as Measured by NCI-CTCAE Version 5.0 [Through 30 days after completion of treatment (estimated to be 4 months)]

   -Toxicity and tolerability will be measured by all immune-related and serious adverse events

3. Overall Survival (OS) [Through 2 years after completion of treatment (estimated to be 27 months)]

4. Progression-free Survival (PFS) [Through 2 years after completion of treatment (estimated to be 27 months)]

   -PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histologically or cytologically confirmed squamous or non-squamous non-small cell lung cancer. Patients with known EGFR or ALK mutations are eligible only if they have received at least one line of targeted therapy for these mutations.

• Availability of archival biopsy tissue or willingness to undergo a "baseline" biopsy prior to initiation of the trial for biomarker analysis, including PD-L1 by IHC. Note: Results of PD-L1 testing are not required for enrollment.

• Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam.

• Prior use of an immune checkpoint blocker alone or in combination therapy.

• At least 18 years of age.

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

• Normal bone marrow and organ function as defined below:

• Absolute neutrophil count ≥ 1,500/cumm

• Platelets ≥ 100,000/cumm

• Hemoglobin ≥ 9.0 g/dL

• Total bilirubin ≤ 1.5 x ULN

• AST(SGOT)/ALT(SGPT) ≤ 3.0 x ULN or 5.0 x ULN in the setting of liver metastasis

• Serum creatinine ≤ 1.5 x ULN or CrCl ≥ 40 mL/min. if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed

• Adequate coagulation function as defined by:

• INR ≤ 1.5

• PTT/aPTT < 1.5 x ULN

• Note: Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH). If receiving warfarin, the patient must have an INR ≤3.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices).

• Urinary protein ≤ 1+ on dipstick or routine urinalysis; if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine collection for protein must demonstrate < 1000 mg of protein in 24 hours to allow participation

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

• Treatment with cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1.

*Note: Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or premedication for contrast dye allergy) are eligible. The use of inhaled corticosteroids for chronic obstructive pulmonary disease (COPD) and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

• A history of other malignancy ≤ 3 years previous with the exception of patients with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per SOC management (e.g., Rai Stage 0 chronic lymphocytic leukemia, prostate cancer with Gleason score ≤ 6 and prostate-specific antigen (PSA ≤ 10 ng/mL, etc.).

• Currently receiving any other investigational agents.

• Symptomatic or untreated asymptomatic brain metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to randomization, or after surgical resection performed at least 28 days prior to randomization. The patient may have no evidence of Grade ≥1 CNS hemorrhage based on pretreatment MRI or IV contrast CT scan (performed within 21 days before randomization).

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to atezolizumab, ramucirumab, any other immune checkpoint blockade, chimeric or humanized antibodies, fusion proteins, or other agents used in the study.

• Receiving chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted.

• Arterial or venous thromboembolic event, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, within 6 months prior to enrollment.

• Uncontrolled or poorly controlled hypertension (> 160 mmHg systolic or > 100 mmHg diastolic for > 4 weeks) despite standard medical management.

• Gastrointestinal perforation, and/or fistula, or risk factors for perforation within 6 months prior to enrollment.

• Grade 3 or 4 gastrointestinal bleeding within 3 months prior to enrollment.

• History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis.

*Note: Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible.

• History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan.

• Hemoptysis (defined as bright red blood or ≥ ½ teaspoon) within 2 months prior to Cycle 1 Day 1 or with radiographic evidence of intratumor cavitation or radiologically documented evidence of major blood vessel invasion or encasement by cancer.

• Serious or non-healing would, ulcer, or bone fracture within 28 days prior to Cycle 1 Day 1.

• Undergone major surgery within 28 days prior to Cycle 1 Day 1, or minor surgery/subcutaneous venous access device placement within 7 days prior to Cycle 1 Day 1, or has elective or planned major surgery to be performed during the course of the clinical trial.

• Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis at a level of Child-Pug B or worse, cirrhosis (any degree) with a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis (defined as ascites from cirrhosis requiring diuretics or paracentesis), fatty liver, and inherited liver disease.

--Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as, HBV surface antigen (HBsAg) positive and HBV core antibody (HbcAb) positive with reflex positive HBV DNA. Note: Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and a positive HBcAb test or treated HCV with negative HCV RNA are eligible.

• Known HIV-positivity.

• Active tuberculosis.

• Administration of a live, attenuated influenza vaccine within 4 weeks before Cycle 1 Day 1 or at any time during the study.

• Severe infections within 2 weeks prior to Cycle 1 Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia. Received oral or intravenous (IV) antibiotics within 2 weeks prior to Cycle 1 Day 1. Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible.

• History of deep venous thrombosis, pulmonary embolism, or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered "significant") during the 3 months prior to Cycle 1 Day 1.

• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days of study entry.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Washington University School of Medicine	Saint Louis	Missouri	United States	63110

Sponsors and Collaborators

• Washington University School of Medicine
• Eli Lilly and Company

Investigators

• Principal Investigator: Daniel Morgensztern, M.D., Washington University School of Medicine

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Apr 27, 2020

More Information

Additional Information:

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Publications

None provided.

• Responsible Party: Washington University School of Medicine
• ClinicalTrials.gov Identifier: NCT03689855
• Other Study ID Numbers: 201810163
• First Posted: Oct 1, 2018
• Last Update Posted: Aug 11, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: Yes
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Atezolizumab; Ramucirumab

Study Results

Participant Flow

Arm/Group Title	Ramucirumab + Atezolizumab
Arm/Group Description	Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.
Period Title: Overall Study
STARTED	21
COMPLETED	17
NOT COMPLETED	4

Baseline Characteristics

Arm/Group Title	Ramucirumab + Atezolizumab
Arm/Group Description	Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.
Overall Participants	21
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	67
Sex: Female, Male (Count of Participants)
Female	17 81%
Male	4 19%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%
Not Hispanic or Latino	21 100%
Unknown or Not Reported	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	5 23.8%
White	16 76.2%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	21 100%

Outcome Measures

1. Primary Outcome

Title	Overall Response Rate (ORR)
Description	ORR: percentage of participants with a complete or partial response Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time Frame	At 6 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Ramucirumab + Atezolizumab
Arm/Group Description	Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.
Measure Participants	21
Count of Participants [Participants]	1 4.8%

2. Secondary Outcome

Title	Clinical Benefit Rate (CBR)
Description	CBR is defined as the percentage of patients who have achieved responses (complete or partial) or stable disease. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time Frame	At 6 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Ramucirumab + Atezolizumab
Arm/Group Description	Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.
Measure Participants	21
Count of Participants [Participants]	16 76.2%

3. Secondary Outcome

Title	Toxicity and Tolerability as Measured by NCI-CTCAE Version 5.0
Description	-Toxicity and tolerability will be measured by all immune-related and serious adverse events
Time Frame	Through 30 days after completion of treatment (estimated to be 4 months)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

4. Secondary Outcome

Title	Overall Survival (OS)
Time Frame	Through 2 years after completion of treatment (estimated to be 27 months)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

5. Secondary Outcome

Title	Progression-free Survival (PFS)
Description	-PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Time Frame	Through 2 years after completion of treatment (estimated to be 27 months)

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	Adverse events are being collected from start of treatment through 30 days after the last administration of the study treatment. All-cause mortality is being collected from start of treatment until completion of follow-up (estimated to be 2 years after completion of study treatment). One participant is still receiving active treatment and treatment can be given until disease progression. The median length of treatment to date is 91.5 days (full range 49 days-812 days).
Arm/Group Title	Ramucirumab + Atezolizumab
Arm/Group Description	Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg. Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg.
All Cause Mortality
	Ramucirumab + Atezolizumab
	Affected / at Risk (%)	# Events
Total	13/21 (61.9%)
Serious Adverse Events
	Ramucirumab + Atezolizumab
	Affected / at Risk (%)	# Events
Total	10/21 (47.6%)
Cardiac disorders
Atrial fibrillation	1/21 (4.8%)
Pericardial effusion	1/21 (4.8%)
Gastrointestinal disorders
Ascites	1/21 (4.8%)
General disorders
Non-cardiac chest pain	1/21 (4.8%)
Hepatobiliary disorders
Portal hypertension	1/21 (4.8%)
Infections and infestations
COVID-19	2/21 (9.5%)
Urinary tract infection	1/21 (4.8%)
Injury, poisoning and procedural complications
Infusion related reaction	1/21 (4.8%)
Metabolism and nutrition disorders
Hyponatremia	1/21 (4.8%)
Nervous system disorders
Headache	1/21 (4.8%)
Stroke	1/21 (4.8%)
Transient ischemic attacks	1/21 (4.8%)
Vocal cord paralysis	1/21 (4.8%)
Respiratory, thoracic and mediastinal disorders
Atelectasis	1/21 (4.8%)
Dyspnea	1/21 (4.8%)
Vascular disorders
Hypertension	1/21 (4.8%)
Hypotension	1/21 (4.8%)
Other (Not Including Serious) Adverse Events
	Ramucirumab + Atezolizumab
	Affected / at Risk (%)	# Events
Total	21/21 (100%)
Blood and lymphatic system disorders
Anemia	9/21 (42.9%)
Ear and labyrinth disorders
Ear pain	1/21 (4.8%)
Endocrine disorders
Hypothyroidism	4/21 (19%)
Eye disorders
Eye pain	1/21 (4.8%)
Gastrointestinal disorders
Abdominal pain	1/21 (4.8%)
Colitis	1/21 (4.8%)
Constipation	5/21 (23.8%)
Diarrhea	6/21 (28.6%)
Dyspepsia	1/21 (4.8%)
Dysphagia	2/21 (9.5%)
Mucositis oral	1/21 (4.8%)
Nausea	11/21 (52.4%)
Oral pain	1/21 (4.8%)
Stomach pain	1/21 (4.8%)
Vomiting	8/21 (38.1%)
General disorders
Chills	4/21 (19%)
Edema limbs	4/21 (19%)
Fatigue	9/21 (42.9%)
Non-cardiac chest pain	2/21 (9.5%)
Pain	2/21 (9.5%)
Infections and infestations
Conjunctivitis	1/21 (4.8%)
Sinusitis	1/21 (4.8%)
Skin infection	1/21 (4.8%)
Thrush	1/21 (4.8%)
Upper respiratory infection	3/21 (14.3%)
Urinary tract infection	3/21 (14.3%)
Vulval infection	1/21 (4.8%)
Investigations
Alanine aminotransferase increased	3/21 (14.3%)
Alkaline phosphatase increased	4/21 (19%)
Aspartate aminotransferase increased	1/21 (4.8%)
Creatinine increased	4/21 (19%)
Hemoglobin increased	2/21 (9.5%)
Lipase increased	1/21 (4.8%)
Lymphocyte count decreased	5/21 (23.8%)
Neutrophil count decreased	3/21 (14.3%)
Platelet count decreased	4/21 (19%)
Serum amylase increased	3/21 (14.3%)
Thyroid stimulating hormone increased	7/21 (33.3%)
Weight loss	6/21 (28.6%)
White blood cell decreased	3/21 (14.3%)
Metabolism and nutrition disorders
Anorexia	10/21 (47.6%)
Dehydration	1/21 (4.8%)
Hypercalcemia	1/21 (4.8%)
Hyperglycemia	3/21 (14.3%)
Hyperkalemia	2/21 (9.5%)
Hypoalbuminemia	6/21 (28.6%)
Hypocalcemia	4/21 (19%)
Hypoglycemia	2/21 (9.5%)
Hyponatremia	6/21 (28.6%)
Musculoskeletal and connective tissue disorders
Arthralgia	3/21 (14.3%)
Flank pain	1/21 (4.8%)
Generalized muscle weakness	2/21 (9.5%)
Hernia right groin	1/21 (4.8%)
Myalgia	5/21 (23.8%)
Neck pain	1/21 (4.8%)
Osteonecrosis of jaw	1/21 (4.8%)
Pain in extremity	1/21 (4.8%)
Pain right groin	1/21 (4.8%)
Rib pain	1/21 (4.8%)
Nervous system disorders
Cognitive disturbance	2/21 (9.5%)
Dizziness	4/21 (19%)
Dysgeusia	2/21 (9.5%)
Dysphasia	1/21 (4.8%)
Extrapyramidal disorder	1/21 (4.8%)
Headache	8/21 (38.1%)
Memory impairment	1/21 (4.8%)
Peripheral motor neuropathy	1/21 (4.8%)
Peripheral sensory neuropathy	1/21 (4.8%)
Somnolence	2/21 (9.5%)
Psychiatric disorders
Anxiety	2/21 (9.5%)
Confusion	1/21 (4.8%)
Delirium	1/21 (4.8%)
Depression	2/21 (9.5%)
Insomnia	2/21 (9.5%)
Renal and urinary disorders
Hematuria	4/21 (19%)
Proteinuria	13/21 (61.9%)
Reproductive system and breast disorders
Pelvic pain	1/21 (4.8%)
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis	3/21 (14.3%)
Cough	8/21 (38.1%)
Dyspnea	4/21 (19%)
Epistaxis	2/21 (9.5%)
Hemoptysis	1/21 (4.8%)
Hiccups	1/21 (4.8%)
Nasal congestion	1/21 (4.8%)
Oropharyngeal pain	1/21 (4.8%)
Productive cough	1/21 (4.8%)
Sore throat	2/21 (9.5%)
Skin and subcutaneous tissue disorders
Alopecia	1/21 (4.8%)
Hyperhidrosis	1/21 (4.8%)
Nail ridging	1/21 (4.8%)
Rash maculo-papular	1/21 (4.8%)
Vascular disorders
Hot flashes	1/21 (4.8%)
Hypertension	17/21 (81%)
Hypotension	2/21 (9.5%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.